Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion versus placebo for fatigue in multiple sclerosis
IRCT20120215009014N465Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Routine treatment + bupropion with Routine treatment + placebo (2 arms). Primary endpoints: Fatigue, Quality of life and 1 more. Started Apr 2023; status: completed.
02
Drugs
bupropion
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20120215009014N465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N465.